TITLE

Serum Uric Acid: Novel Prognostic Factor in Primary Systemic Amyloidosis

AUTHOR(S)
Shaji Kumar; Dispenzieri, Angela; Lacy, Martha Q.; Hayman, Suzanne R.; Leung, Nelson; Zeldenrust, Steve R.; Buadi, Francis K.; Kyle, Robert A.; Rajkumar, S. Vincent; Gertz, Morie A.
PUB. DATE
March 2008
SOURCE
Mayo Clinic Proceedings;Mar2008, Vol. 83 Issue 3, p297
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To determine the prognostic value of serum uric acid (UA) in patients with primary systemic (light chain) amyloidosis (AL). PATIENTS AND METHODS: A cohort of 1977 patients with newly diagnosed AL seen at our institution between April 1, 1960, and August 1, 2006, and 293 patients with AL who underwent peripheral blood stem cell transplant between March 1, 1996, and October 1, 2006, were studied retrospectively to examine the value of serum UA. The prognostic value of several variables was examined using Cox proportional hazards models, and the survival time was estimated using Kaplan-Meier analysis; curves were compared using the log-rank test. RESULTS: Patients with UA levels greater than 8 mg/dL had a median overall survival of 9 months from diagnosis compared with 20.3 months for the remaining patients (P<.001). The prognostic value of UA was independent of the known cardiac prognostic markers cardiac troponin T (cTnT) and N-terminal propeptide of brain-type natriuretic peptide (NTProBNP). Addition of UA to these factors allows us to classify patients into 4 groups with significantly different outcomes. Patients with none, 1, 2, or 3 of these risk factors (UA, >8 mg/dL; cTnT, >0.035 ng/mL; and NTProBNP, >332 pg/mL) had a median overall survival of 36.6, 29.2, 11.1, and 3.6 months, respectively (P<.001). Similarly, UA levels helped predict overall survival in patients undergoing peripheral blood stem cell transplant for AL and added to the value of cTnT and NTProBNP. CONCLUSION: The data confirm the prognostic utility of cTnT and NTProBNP in a large group of patients and highlight the value of serum UA in allowing better forecasting of probable outcomes for patients with AL.
ACCESSION #
31154400

 

Related Articles

  • LARYNGEAL AMYLOIDOSIS: LOCALIZED VERSUS SYSTEMIC DISEASE AND UPDATE ON DIAGNOSIS AND THERAPY. Bartels, Hilke; Dikkers, Frederik G.; Lokhorst, Henk M.; van der Wal, Jacqueline E.; Hazenberg, Bouke P.C. // Annals of Otology, Rhinology & Laryngology;Sep2004, Vol. 113 Issue 9, p741 

    The clinical and pathological characteristics, possibility of systemic disease, and effect of local therapy were studied in laryngeal amyloidosis. Records of all patients with localized laryngeal amyloidosis in a single tertiary referral center were examined retrospectively at diagnosis and...

  • Skin Involvement in Generalized Amyloidosis. Rubinow, Alan; Cohen, Alan S. // Annals of Internal Medicine;Jun78, Vol. 88 Issue 6, p781 

    Provides information on a study which examined clinically involved and uninvolved skin in 50 patients with primary and secondary amyloidosis. Description of primary and multiple myeloma-associated amyloidosis; Extent of amyloid involvement in skin biopsies in primary and multiple...

  • Beta 2-microglobulin metabolism in uremic patients who are undergoing dialysis. Chanard, Jacques; Vincent, Claude; Caudwell, Valerie; Lavaud, Sylvie; Toupance, Olivier; Wong, Tony; Revillard, Jean-Pierre // Kidney International Supplement;Jun1993, Issue 41, pS-83 

    Plasma beta 2-microglobulin (β2m) is increased in chronically hemodialyzed patients and remains in a steady range once residual diuresis has stopped. Factors controlling such a steady state are unknown. We undertook metabolic studies to define whether plasma β2m is regulated by extrarenal...

  • Imaging cardiac amyloidosis: a pilot study using F-florbetapir positron emission tomography. Dorbala, Sharmila; Vangala, Divya; Semer, James; Strader, Christopher; Bruyere, John; Carli, Marcelo; Moore, Stephen; Falk, Rodney // European Journal of Nuclear Medicine & Molecular Imaging;Sep2014, Vol. 41 Issue 9, p1652 

    Purpose: Cardiac amyloidosis, a restrictive heart disease with high mortality and morbidity, is underdiagnosed due to limited targeted diagnostic imaging. The primary aim of this study was to evaluate the utility of F-florbetapir for imaging cardiac amyloidosis. Methods: We performed a pilot...

  • Transmission of Mouse Senile Amyloidosis. Xing, Yanming; Nakamura, Akihiro; Chiba, Takuya; Kogishi, Kumiko; Matsushita, Takatoshi; Li, Fu; Guo, Zhanjun; Hosokawa, Masanori; Mori, Masayuki; Higuchi, Keiichi // Laboratory Investigation (00236837);Apr2001, Vol. 81 Issue 4, p493 

    In mouse senile amyloidosis, apolipoprotein A-II polymerizes into amyloid fibrils (AApoAII) and deposits systemically. Peripheral injection of AApoAII fibrils into young mice induces systemic amyloidosis (Higuchi et al, 1998). We isolated AApoAII amyloid fibrils from the livers of old...

  • Diyaliz iliÅŸkili amiloidozisin high flux ve standart hemodiyaliz tedavisinde radyolojik ve sintigrafik bulguları. Çelik, Gülperi; Demirpolat, Gülgün // Genel Tip Dergisi;2009, Vol. 19 Issue 4, p177 

    Objective: This study was undertaken to evaluate the radiological and scintigraphic findings of amyloidosis related with dialysis after treatment of high flux (HF) and standard (STD) hemodialysis (HD). Methods: This study included a total of 16 standard HD and 16 HF HD patients who were treated...

  • Clinical presentation, treatment, and prognosisof periocular and orbital amyloidosisin a university-based referral center. Aryasit, Orapan; Preechawai, Passorn; Kayasut, Kanita // Clinical Ophthalmology;Apr2013, Vol. 7, p801 

    Objective: The purpose was to present the demographic data, clinical presentation, and treatment options, and to evaluate prognosis, for periocular and orbital amyloidosis in patients at the Songklanagarind Hospital, Thailand. Method: This was a retrospective study that reviewed the clinical...

  • Managing the Patient with Amyloidosis. Cannon, Jan D.; Pullen, Richard L.; Rushing, Jill D. // Dermatology Nursing;Jun2004, Vol. 16 Issue 3, p225 

    Amyloidosis is a rare disease characterized by extracellular protein deposits in various tissues and vital organs of the body, which often leads to severe and debilitating chronic health problems and death. Early recognition symptoms, prompt diagnosis and treatment, and nursing care are...

  • Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice. Li, Song; Hou, Huayan; Mori, Takashi; Sawmiller, Darrell; Smith, Adam; Tian, Jun; Wang, Yanjiang; Giunta, Brian; Sanberg, Paul R.; Zhang, Sheqing; Tan, Jun // Scientific Reports;6/19/2015, p11322 

    BACE1 initiates amyloid-β (Aβ) generation and the resultant cerebral amyloidosis, as a characteristic of Alzheimer's disease (AD). Thus, inhibition of BACE1 has been the focus of a large body of research. The most recent clinical trials highlight the difficulty involved in this type of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics